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ABSTRACT
In general, splicing regulatory elements are
defined as Enhancers or Silencers depending on
their positive or negative effect upon exon
inclusion. Often, these sequences are usually
present separate from each other in exonic/
intronic sequences. The Composite Exonic
Splicing Regulatory Elements (CERES) represent
an extreme physical overlap of enhancer/silencer
activity. As a result, when CERES elements are
mutated the consequences on the splicing process
are difficult to predict. Here, we show that the func-
tional activity of the CERES2 sequence in CFTR
exon 12 is regulated by the binding, in very close
proximity to each other, of several SR and hnRNP
proteins. Moreover, our results show that practically
the entire exon 12 sequence context participate in
its definition. The consequences of this situation
can be observed at the evolutionary level by
comparing changes in conservation of different
splicing elements in different species. In conclusion,
our study highlights how it is increasingly difficult to
define many exonic sequences by simply breaking
them down in isolated enhancer/silencer or even
neutral elements. The real picture is close to one
of continuous competition between positive and
negative factors where affinity for the target
sequences and other dynamic factors decide the
inclusion or exclusion of the exon.
INTRODUCTION
Only a few years ago, mutations in the protein-coding
section of genes that did not aﬀect amino acid coding
capacities were considered to be neutral with regards
to the protein functional properties (and thus the
evolutionary ﬁtness of the gene). Since then, advances in
both the pre-mRNA splicing and the translational
research ﬁelds have severely challenged this assumption,
especially with regards to its implications in the occur-
rence of human disease and on evolutionary mech-
anisms in general (1–3). With regards to the pre-mRNA
alternative splicing process (4), this assumption was
ﬁrst challenged by the discovery that splicing regula-
tory elements (SREs) could be found embedded within
exonic coding sequences both in alternative and consti-
tutive splicing (5,6) and that these elements and the
strength of the basic splicing consensus motifs (7) could
regulate exon inclusion levels. More than 20 years since
these discoveries, the importance of splicing regula-
tory regions within exon coding sequences has, if
anything, greatly increased. In fact, global analyses
of splicing events (8,9) and the search for these splicing
regulatory motifs embedded within exons has received
considerable attention, especially through the use of
high-throughput and bioinformatics approaches (10,11).
The results of all these analyses clearly indicate that
SRE elements represent important players in control-
ling both alternatively and constitutively splicing pro-
cesses (12,13).
In general, SRE elements are individually referred to as
Exonic and Intronic Splicing Enhancers (ESEs and ISEs)
or Exonic and Intronic Splicing Silencers (ESSs and ISSs)
sequences depending on their localization and func-
tional eﬀects (14–18). The way in which SRE elements
exert their action is through the binding of trans-acting
factors, predominantly belonging to the SR and hnRNP
protein families (19–23). It should be noted, however,
that the list of proteins capable of modulating splicing is
growing every year (24) and much still remains to be
uncovered in this area of research. Nonetheless, aside
from individual identities, it has been determined long
ago that the balance between antagonistic factors
binding to a particular SRE element is one key factor
in discriminating exon inclusion/exclusion levels (25,26).
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great advantage to the eukaryotic cell because, whenever
necessary, it can be shifted in one direction or the other
through several mechanisms. In fact, beside the intrinsic
aﬃnity of splicing factors for their respective cis-targets,
the binding level of each factor can be easily modiﬁed by
variations in its relative expression levels (27–29),
posttranslational modiﬁcations (30–33) or local RNA
folding arrangements that limit/enhance their availability
(34–39).
Studying these issues also makes for fascinating insights
with regards to the potential relationships between coding
and splicing regulatory regions during the course of evo-
lution. It is now clear, in fact, that synonymous or even
advantageous substitutions at the protein level may still be
selected against if they end up to be harmful with regards
to splicing decisions. On the other hand, suboptimal
codon usage arrangements may be maintained to
preserve correct splicing functionality (1,40). In keeping
with this concept, recent analyses have uncovered the
presence of extensive purifying selection against sub-
stitutions in ESE elements as determined by the reduced
single nucleotide polymorphism density in these regions
(41) and by the fact that codon usage at the exon–intron
boundaries may be considerably aﬀected by the need to
maintain SRE sequences (42). It should also be men-
tioned, however, that these kind of analyses are still
hampered by our limited knowledge of SRE sequences
and caution should be employed when making these
kind of comparisons on the basis of bioinformatic
studies (43). For this reason, it is advisable to back up
any eventual conclusion with functional experiments
that might either support or not the bioinformatics
considerations.
Among the known SRE sequences, a particularly
interesting class of elements is represented by the discov-
ery of the Composite Exonic Regulatory Elements of
Splicing (CERES), that were ﬁrst identiﬁed in human
CFTR exon 12 and exon 9 (44,45). Unlike the classical
exonic regulatory elements, that tend to predomi-
nantly possess either enhancing or silencing properties,
the eﬀect of mutagenesis in CERES elements is very
unpredictable with regards to splicing outcomes. This
makes it very diﬃcult to evaluate the potential patho-
logic eﬀect of apparently benign substitutions in these
regions. In this work, we have combined the analysis
of natural pathogenic mutations with a comparative
human–mouse genomic approach to better understand
the characteristics of one of these CERES elements
in CFTR exon 12 (CERES2). The results of this analysis
have reinforced the emerging concept that in many
cases dividing exonic sequences in well deﬁned enhancer/
silencer or neutral splicing regulatory elements does
not satisfactorily explain anymore the eﬀects of artiﬁcial
and natural substitutions. It is only by adopting a more
global view of splicing regulatory codes that will allow
us to understanding many dynamic sequence interplays




Human CFTR exon 12 minigene constructs (T40C, G48C,
A49G, A51T, C52T and WT) have been previously
described (40,44). Further modiﬁcation of the exon were
introduced by PCR-directed mutagenesis using speciﬁc
primers and cloned inside the NdeI restriction site of the
pTB plasmid. Primer sequences for each described
mutants can be provided up on request. Mouse CFTR
Exon 12 along with the mouse introns (297nt of intron
11 and 219nt of intron 12) was ampliﬁed from genomic
DNA (Mus musculas strain C57BL/6) using primers
MCF12 F: 50-ggctccaggcttgagcatatgtactaatctg-30 and
MCF12 R: 50-caagaaattggcttcatatgtgatcatcaga-30. Mouse
CFTR exon 12 modiﬁcations were also performed by
PCR-directed mutagenesis with speciﬁc primers.
CFTR exon 12 sequences of diﬀerent animals were
recovered using NCBI BLASTN search. Accession
numbers of the sequences are Human (Gene Bank acces-
sion number NM_000492.3 Homo sapiens), Guinea pig
(Gene Bank accession number AF133216.1 Cavia
porcellus), Ground Squirrel (Gene Bank accession number
AC184040.3 Spermophilus tridecemlineatus), Mouse (Gene
Bank accession number NM_021050.2 Mus musculus),
Rabbit (Oryctolagus cuniculus) GenBank accession no.
NM_001082716, Cow (Bos tortus) GenBank accession
no. NM_174018, Pig (Sus scrofa) GenBank accession no.
AY585334, Horse (Equus caballus) GenBank accession
no. NM_001110510, Lemur (Lemur catta) GenBank acces-
sion no. AC123543.
Cell culture, transfections and RT–PCR analysis
HeLa cells were cultured in Dulbecco’s modiﬁed Eagle’s
medium with Glutamax (Invitrogen) in standard
conditions. The minigenes used for transfection were
puriﬁed using phenol–choloroform extraction followed
by a sephacryl S-400 (GE healthcare) column puriﬁcation
step. HeLa cells were plated at a concentration of
2.8 10
5 to achieve 80–90% conﬂuence. The following
day, 500ng of plasmid DNA were transfected in the
cells using Eﬀectene transfection reagents (Qiagen). In
case of in vivo overexpression of SR proteins (a kind gift
from J. Caceres), 1mg of expression vector was mixed with
500ng of minigenes. Finally, after 24h total RNA was
extracted using TRIreagent solution (Ambion). One
microgram of total RNA was used in the retrotran-
scription reaction with random primers and Moloney
murine leukemia virus enzyme (Invitrogen). Spliced
products from the transfected minigene were obtained
using primers Bra2 50-taggatccggtcaccaggaagttggttaaat
ca-30 and a 2–3 50-caacttcaagctcctaagccactgc-30. PCR
conditions were the following: 94 C for 5min.; 94 C for
30s, 55 C for 30s, and 72 C for 30s for 30cycles; and
72 C for 7min for the ﬁnal extension. PCRs were
optimized to be in the exponential phase of ampliﬁcation
and products were routinely fractionated in 1.8% (wt/vol)
agarose gels.
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RNA was transcribed from PCR templates ampliﬁed from
the respective plasmids. A T7 promoter sequence was
added towards the 50-end of the template using primer
carrying T7 sequence and, similarly, a (TG)8 repeated
sequence was used to tag the 30-end. Every time, 5mgo f
DNA template was used in a 60ml T7 polymerase
(Stratagene) transcription reaction. The RNA was then
puriﬁed using standard Acid–Phenol puriﬁcation method
followed by Ethanol precipitation. Synthetic RNA oligos
corresponding to Mouse 17–38, Human 17–38, Mouse
63–81 and Human 63–81 sequences were purchased from
Euroﬁns MWG Operon, Germany.
Aﬃnity puriﬁcation of RNA binding proteins and
western blot analysis
Ten micrograms of synthetic RNA oligo or 15mgo f
transcribed RNA were oxidized in the dark for an hour
with sodium m-periodate in a 400ml reaction mixture
(100mM Sodium acetate pH 5.2 and 5mM Sodium
m-periodate). RNA was then ethanol precipitated and
resuspended in 200ml of 100mM sodium acetate.
Approximately 350ml of prewashed equilibrated adipic
acid dehydrazide-agarose beads (50% slurry; Sigma)
were added to each oxidized RNA volume and placed in
the rotor at 4 C for overnight incubation. This RNA-Bead
covalent link formation was also performed in the dark.
The immobilized RNA were then washed once with 1ml
of 2M NaCl and twice using washing buﬀer (5.2mM
HEPES pH 7.5, 1mM MgCl2, 0.8mM Mg acetate).
Meanwhile, 200ml of nuclear extract was mixed with
900ml RNAse free water, 1  binding buﬀer (5.2mM
HEPES pH 7.9, 1mM MgCl2, 0.8mM Mg acetate,
0.52mM dithiothreitol, 3.8% glycerol, 0.75mM ATP,
1mM GTP and Heparin at the ﬁnal concentration of
0.5mg/ml). The RNA-bound beads were then equilibrated
in 300ml of NE mix and incubated for 25min on a rotor at
room temperature. Beads were then washed four times
with 1.5ml washing buﬀer. In every washing step beads
were gently precipitated by gravity on ice. Finally, 50ml
of 3  SDS loading buﬀer was added and samples
were heated for 5min before loading on a 10% SDS–
polyacrylamide denaturing gel. The gel was then
electroblotted onto a polyvinylidene diﬂuoride
membrane according to standard protocols (Amersham
Biosciences) and blocked with 10% skimmed milk (Non
fat dry milk in 1  PBS). Membranes targeted for SR
protein recognition were blocked using Western blocking
reagent (Roche). Proteins were probed with diﬀerent
antibodies and detected with a chemiluminescence kit
(ECL; Pierce Biotechnology). Antibodies against hnRNP
U and Tra2 b were kind gifts from G. Dreyfuss and I.C
Eperon, respectively. Monoclonal Anti-ASF/SF2, SC35
and 1H4 (against SRp 75, 55, 40) antibodies were
purchased from Zymed Laboratories Inc. Changes of
protein binding levels have been quantiﬁed relative to
TDP-43 using an Ultro Scan XL, Pharmacia LKB—
laser densitometer at 633nM wavelength according to
manufacturer’s instructions.
siRNA knockdown of splicing factors
siRNA sense sequences used for silencing the diﬀerent
target proteins were the following: human hnRNPA1—
cagcugaggaagcucuuca (Sigma), and human hnRNPA2—
ggaacaguuccguaagcuc (Sigma); human hnRNP C1/C2-
gcaaacaagcaguagagau (Sigma), human DAZAP1-
gagacucugcgcagcuacu (Dharmacon) and luciferase no. 2
gene control, gccauucuauccucuagaggaug (Dharmacon).
HeLa cells were plated at 0.7 10
5cells per well in
35-mm plates to achieve 30–40% conﬂuence. The next
day, 3ml Oligofectamine (Invitrogen) was combined with
15ml of Opti-MEM medium (Invitrogen) and 3mlo f
40mM siRNA duplex oligonucleotides was diluted in a
ﬁnal volume of 180ml of Opti-MEM medium. The two
mixtures were combined and left for 20min at room tem-
perature. Finally, this mixture was added to the cells,
which were mantained in 0.9ml of Opti-MEM only.
After 6h, 500ml of 30% FBS (Foetal bovine serum,
Invitrogen) was added. Six to eight hours later Opti-
MEM was exchanged with Dulbecco’s modiﬁed Eagle
medium and the cells were transfected with the minigene
of interest (500ng) using Qiagen Eﬀectene transfection
reagents. On the third day, HeLa cells were harvested
for protein and RNA extractions. RT–PCR from total
RNA was performed as for the transfection protocol
described above. Whole-protein extracts were obtained
by cell sonication in lysis buﬀer (1  PBS and 1 
Protease inhibitor cocktail) and analyzed for hnRNPA1,
A2, C1/C2 and DAZAP1 endogenous protein expression
by immunoblotting using the antibodies described above.
Tubulin was used as total protein loading control.
RESULTS
In order to better characterize the CERES2 element in
CFTR exon 12 we selected two pathological missense
mutations (G48C, A51T) and three samesense
substitutions (T40C, A49G and C52T) that were already
known to aﬀect CFTR exon 12 splicing when inserted in
the pTB minigene (Figure 1). In particular, transfection in
HeLa cells of the G48C and A49G substitutions caused
exon skipping in the full exon 12 context whilst A51T
caused full exon inclusion, as previously reported (44).
In addition, to widen the number of mutations under
study we also chose the T40C and C52T synonymous
substitutions that were already known to cause total
exon skipping when inserted in the human context (40).
These substitutions are particularly interesting form an
evolutionary point of view as they are naturally present
in the mouse CFTR exon 12 sequence and C52T has
also been reported as a human polymorphism/possible
mutation in the Cystic Fibrosis Mutation Database
(www.genet.sickkids.on.ca). The position and con-
sequences of all these substitutions when inserted in a
CFTR exon 12 minigene are summarized in Figure 1A
and B, respectively.
First of all, we were interested to see whether the func-
tional eﬀects of these substitutions were dependent on
the context provided by the rest of the exon sequence.
To study this, we have analyzed their functional eﬀect in
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removing the regions near the 3 and 50s and downstream
regions but maintaining 4 and 3 nts close to the 30 intron-
exon and exon-50 intron junctions, respectively. We called
this construct ‘mini’ exon 12 (Figure 1C, upper panel).
When all the mutations analyzed in Figure 1B were
inserted in this reduced context both the G48C and
A49G were still capable of inducing exon skipping as
observed in the full length exon 12, whilst the enhancing
eﬀect of A51T could not be observed owing to the fact
that the wild-type mini exon 12 is fully included in
the spliced transcript (as opposed to only 80% inclusion
of the full length exon 12) (Figure 1C, lower panel).
Interestingly, both mouse-speciﬁc T40C and C52T
substitutions lost the ability to induce exon skipping, sug-
gesting that their eﬀect on the CFTR exon 12 splicing
process necessitated the presence of either one or both
human ﬂanking regions (Figure 1C, lower panel and
Figure 6).
Identifying the trans-acting factors whose binding is
aﬀected by these substitutions
Considering that overexpression of the classical splicing
factors hnRNP A1 and SF2/ASF was already described
to aﬀect CFTR exon 12 splicing (44) it was decided to
better characterize the eﬀect of these substitutions in
terms of binding to a wide range of SR and hnRNP
splicing factors. To achieve this, we have used a
pulldown system previously used in our lab to identify
speciﬁc RNA binding proteins in a variety of exonic/
intronic contexts (46,47). The transcribed RNAs carry a
(UG)8 tail that functions as a loading control for the
TDP-43 protein (48) (Figure 2A).
In the ﬁrst analysis, we tested the mini wild-type CFTR
exon 12 sequence and two versions carrying the two
missense mutations G48C and A51T for binding to the
following proteins: hnRNP U, PTB, hnRNP H,
DAZAP1, hnRNP C2, A1, A2 and SRp75, SRp55,
SRp40, SF2/ASF and Tra2b. The results of this analysis
are reported in Figure 2B. This ﬁgure shows that no
binding could be observed for the hnRNP H, PTB,
SRp75, SRp40, SC35 and Tra2b proteins to the mini-
exon 12 sequence, both in its wild-type form and
carrying either the G48C or the A51T mutations. On the
other hand, some of the proteins tested could bind all
these sequences, irrespectively of the presence or absence
of mutations (hnRNP U and SRp55). Interestingly, a few
displayed a diﬀerential binding ability in the wild-type
sequence with respect to these mutations. In particular,
the most striking change could be observed for the SF2/
ASF protein that could better bind the A51T mutant with
respect to the wild-type sequence. At the same time, it
could also bind less eﬃciently to the G48C mutant than
to the wild-type. Finally, hnRNP C2 could also bind less
eﬃciently to the A51T mutant. It is worth noting that
Figure 1. (A) Schematic presentation of the hybrid minigene used in transfection experiments. The a-globin, ﬁbronectin EDB, and human CFTR
exon 12 are shown as black, white and gray boxes, respectively. The sequence of CFTR exon 12 and position of the CERES1 and CERES2 elements
is reported in full. (B and C) Schematic diagram of both full and mini CFTR Ex. 12 constructs used in the analysis. The vertical superimposed
arrows indicate the locations of both natural and synonymous mutations. The ampliﬁed RT–PCR products stained with ethidium bromide are shown
in the bottom panels. Spliced transcripts are shown with Ex.12+ for inclusion and Ex.12  for exclusion of the exon.
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small changes then ampliﬁed by the combinatorial eﬀect
of all the other elements involved. On the other hand, the
A51T mutant that in the whole exon 12 context has
an exon inclusion enhancing eﬀect, displayed increased
SF2/ASF binding levels than the wild-type sequence.
Quantiﬁcation of hnRNP C2 and SF2/ASF binding
levels in these experiments (normalized against TDP-43)
are reported in Figure 2C as determined using
densitometric analysis from three independent exper-
iments.
In the case of the three synonymous mutations (T40C,
A49G and C52T), the pulldown experiments yielded less
varied results (Figure 3B). In fact, no changes could be
observed in the binding proﬁles of RNAs carrying the
T40C and C52T substitutions with respect to the wild-
type sequence. However, in the case of the A49G
mutation we observed less binding of the SF2/ASF
protein than in the wild-type sequence and increased
binding of hnRNP C2 (quantiﬁcation of these proteins
are reported in Figure 3C), a situation that made the
eﬀects of this mutation very similar to those observed
for G48C (Figure 2B). Furthermore, it was also consistent
with its inhibitory eﬀect in the mini-exon 12 minigene
(Figure 1C). In this respect, the observation that no
changes could be observed for any of these proteins
in the case of T40C and C52T was also consistent with
the functional assays demonstrating that these two
substitutions were neutral in the human mini-context
(Figure 1C).
Validating the role played by SR factors in CFTR exon
12 splicing
In order to validate the role played by the SR proteins, we
tested the response of both the G48C and A49G minigenes
to overexpression of the speciﬁc interactors of the mini-
exon 12 sequence, SF2/ASF and SRp55 and of SC35
(as an example of a SR protein not interacting with the
mini exon). The results shown in Figure 4A demonstrate
that both SF2/ASF and SRp55 consistently have a higher
enhancing eﬀect on the mini exon 12 inclusion levels than
SC35, suggesting that direct interaction provides an
advantage over the well known generalized enhancing
eﬀect of SR proteins. Interestingly, however, the enhance-
ment observed for the two mutants was not the same,
with A49G being less responsive especially for SRp55
overexpression than G48C. Finally, it should be noted
that deletion of the central CERES2 region also abolished
completely the response of the mini-exon 12 to all SR
protein overexpression, demonstrating that their action
in the mini-exon context is mediated only through the
CERES2 sequence. In parallel, to further rule out non-
speciﬁc eﬀects of SF2/ASF overexpression, we also per-
formed overexpression analysis of a series of deletion
mutants (Figure 4B). Also in this case, mutants lacking
either the RRM2 region (RRM2) or the RS domain
Figure 2. Western blot analysis of recovered proteins after pulldown of two naturally occurring nonsense CFTR mutations (G48C/G576A and
A51T/Y577F) compared with CFTR Ex. 12 wild type. In vitro transcribed RNA was used for analysis. (A) Transcribed RNA sequences used for
pulldown analysis with the mutations (underlined). A (UG)8 repeat speciﬁc for TDP43 was added at the 30-end of each RNA to normalize the data
after western blot. (B) Aﬃnity assay for binding of the following hnRNPs: U, PTB, H, DAZAP1, C2, A1 and A2. (C) Aﬃnity assay for binding of
the following SR factors: SRp75, SRp55, SRp40, SC35, Tra2b and SF2/ASF. Detection of all these proteins was performed by western blot using
speciﬁc antibodies. Quantiﬁcation of SF2/ASF and hnRNP C2 binding levels as determined by densitometric analysis are reported in Figure 2C
(normalized by TDP-43). Standard deviation values from three independent experiments are shown.
Nucleic AcidsResearch, 2010, Vol.38,No. 2 651Figure 3. Aﬃnity pulldown performed for the three synonymous mutations (T40C, A49G and C52T) in CFTR exon 12. (A) Transcribed RNA
sequences used for pulldown analysis along with their mutations (underlined). A (UG)8 repeat speciﬁc for TDP43 was added at the 30-end of each
RNA for pulldown normalization. (B) Aﬃnity pulldown assay for hnRNPs U, PTB, H, DAZAP1, C2, A1 and A2. (C) Aﬃnity pulldown assay for
SR proteins SRp75, SRp55, SRp40, SC35, Tra2 b and SF2/ASF. Detection of all these proteins was performed by western blot using speciﬁc
antibodies. Quantiﬁcation of SF2/ASF and hnRNP C2 binding levels as determined by densitometric analysis is reported in Figure 3C (normalized
by TDP-43). Standard deviation values from three independent experiments are shown.
Figure 4. (A) Analysis showing the in vivo overexpression of SR proteins (SRp55, SC35 and SF2/ASF) to rescue CFTR exon 12 mutant minigenes in
their mini context. In the case of the CERESdel mini construct, 6nt of CERES2 (GGATAC) was removed. (B) Overexpression of wild-type SF2/
ASF and a series of SF2/ASF mutants (RRM1, RRM2 and RS) in the presence CFTR exon 12 mutant minigenes in their mini context. The
ampliﬁed RT–PCR product of the spliced/unspliced mRNAs are stained using ethidium bromide and run in an agarose 1.8% gel. Exon inclusion and
skipping are is shown by Ex12+ and Ex12 , respectively.
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speciﬁcity of this SR protein functional interaction with
the CERES2 sequence.
Validating the role played by hnRNP factors in CFTR
exon 12 splicing
Because of their abundance in the nuclear extract,
overexpression studies for the diﬀerent hnRNP proteins
did not yield satisfactory results (data not shown). For
this reason, in order to test eﬀectively the functional
eﬀects of the hnRNP interactors found in pulldown
analysis we performed individual siRNA-mediated knock-
down of the well known hnRNP A1, A2 and C2 proteins
(Figure 5A). As shown in Figure 5B, the only siRNA
knockdown that could rescue both the G48C and A49G
mini-exons inclusion was hnRNP A1. Importantly,
knockdown of this protein had no eﬀect on the
CERESdel minigene. Finally, no eﬀect could be detected
following hnRNP C2 knockdown which is rather surpris-
ing considering that the role of this protein in the regula-
tion of splicing control has been recently re-evaluated in
high-throughput studies (23). In addition, as there are
many hnRNPs with redundant functions we have also
tried the simultaneous depletion of A1, A2 and C2 in dif-
ferent combinations but could not conﬁrm their role in the
splicing regulation of CFTR exon 12 (data not shown).
It should be noted, however, that these results do not
mean that only hnRNP A1 can modulate CFTR exon
12 splicing. In fact, some of these proteins could still
play an active role in the presence of reduced amounts
of positive factors (i.e. SF2/ASF or SRp55) and further
work will be needed to clarify this issue.
Recovery of the T40C and C52T inhibitory action
through the add back of human and mouse
ﬂanking CFTR exon 12 sequences
In order to better characterize the mode of action of these
substitutions to the mini-exon 12 minigene, we selectively
added back the missing upstream and downstream
sequences (both in their human and mouse forms) and
observed which mutant was able to recover the inhibitory
eﬀect of the T40C/C52T substitutions (Figure 6A).
As shown in Figure 6B, right panel, the wild type exon
12 constructs that contain the added-back human and
mouse upstream regions display full inclusion (constructs
A and D). However, when we inserted back the T40C and
C52T mutations the inhibitory eﬀect could be detected
only in the constructs with the added back human
sequence but not with those with the mouse sequence
(compare constructs B–C with E–F). A similar situation
could also be observed with the downstream regions.
In fact, Figure 6B, middle panel, shows that wild-type
exon 12 sequences with the added-back human and
mouse downstream region display full inclusion
(constructs G and J). However, when T40C and C52T
were inserted back it was observed that the inhibitory
eﬀect could be detected only in the constructs with the
human but not with the mouse downstream sequence
(compare constructs H–I with K–L). Interestingly, the
integrity of maintaining the mouse polypurinic GAAGA
ACAAG motif present in the mouse sequence (underlined
Figure 5. (A) Knockdown of hnRNP factors in HeLa cells using siRNAs (+) against hnRNP A1, A2 and C2. Luciferase siRNA treated cells have
been used as a control and correct depletion was determined by western blot assay (extracts have been normalized using tubulin) (B) Eﬀects of
transfecting the G48C, A49G and CERESdel minigenes in HeLa cells selectively depleted of each of these hnRNP proteins. RT-PCR samples are
stained with ethidium bromide and run on a 1.8% agarose gel. Exon inclusion and skipping are shown by Ex12+ and Ex12 , respectively.
Nucleic AcidsResearch, 2010, Vol.38,No. 2 653in Figure 6A, bottom) is particularly important. In fact,
the majority of substitutions that tend to restore the
mouse sequence can successfully withstand the inhibitory
action of the C52T substitution (construct N-O as
opposed to M).
Taken together, these results suggest that the human
and mouse ﬂanking regions have diﬀerent splicing regula-
tory properties: human sequences, both upstream and
downstream of the central exon 12 region containing
CERES2, may be predominantly inhibitory. On the
other hand, the mouse upstream and downstream
sequences seem to enhance exon recognition.
The hypothesis that mouse sequences enhanced exon
recognition was thus tested at the functional level by
amplifying a mouse CFTR exon 12 sequence and inserting
it in the pTB minigene system (Figure 7A). In this
sequence, we then deleted the upstream and downstream
regions, either separately or in combination (mutants A–C).
The results of this analysis are reported in Figure 7B and
show that deleting only the upstream sequence (mutant A)
had no eﬀect of mouse CFTR exon 12 inclusion
levels. On the other hand, deletion of the downstream
sequence (mutant B) resulted in  15% exon skipping.
Interestingly, if both regions are deleted at the same
time (mutant C) the levels of exon skipping increase to
25%, indicating that also the polypurinic downstream
sequence can function as an ESE once the upstream
ESE sequence is absent.
Trans-acting factors binding to the human and mouse
17–38 and 63–81 sequences
Based on these results, it was thus likely that mouse and
human ﬂanking sequences could bind a diﬀerent set of
proteins. For this reason, we selected the 17–38 and
63–81 mouse and human regions (Figure 8A) to perform
pulldown assays as previously described for the central
region (Figures 2–3). The Western blot analysis to check
for SR protein binding showed that both mouse sequences
could bind SF2/ASF, SRp75 and SRp55 more eﬃciently
than the respective human sequences. In addition, mouse
nucleotide stretch 64–82 is also capable of binding SRp40
whilst the human 64–82 sequence is not (Figure 8C). As
control, the recognition with antibodies against hnRNP
proteins A1 and U showed that both these factors could
bind with equally well with the mouse and human
sequences. Unfortunately, using this approach we were
unable to determine which factors are responsible for
the ESS activity of the human 18–39 and 64–82 sequences.
Of course, the most probable reason is that we have tested
only a fraction of the candidates and there are many
potential known or unknown proteins that could exert
an eﬀect on splicing regulation. Further work is currently
under way to better deﬁne this point. In any case, these
results were consistent with the in vivo results that detected
diﬀerent functional properties between the mouse and
human ﬂanking regions.
Figure 6. (A) Schematic diagram of the wild-type and hybrid mouse and human CFTR exon 12 sequences used to construct a series of minigenes
(labeled A to O). Nucleotide diﬀerences in the mouse sequence with respect to the human are boxed. Blank spaces in the alignment represent the
sequences removed form the exon. (B) Results of the transfection analysis of the minigenes labeled A to O following transfection in HeLa cells. Exon
inclusion is shown by Ex12+ and skipping Ex12 . RT–PCR samples are stained with ethidium bromide and run on a 1.8% agarose gel.
654 Nucleic Acids Research, 2010, Vol. 38,No. 2DISCUSSION
Missense mutations in human CFTR exon 12 have been
described to be the causative agent of Cystic Fibrosis
through the inactivation of a highly conserved region
that encodes part of the ﬁrst nucleotide binding fold of
the protein (49). In particular, among all disease-causing
mutations known to aﬀect this exon, several have been
described to induce its skipping during the splicing
Figure 7. (A) Schematic analysis of the pTB minigene containing the mouse CFTR exon12 sequence (reported in full). Mouse speciﬁc nucleotides are
boxed. Mutants A, B and C show the combination of nucleotide deletions spanning from nucleotides 23 to 31 and 68 to 76 included (B) Mouse
CFTR exon 12 minigenes (wild-type, A, B and C) were transfected in HeLa cells for in vivo splicing assay. The ampliﬁed RT–PCR products of this
splicing assay are stained by ethidium bromide and run on a 1.8% agarose gels. Exon inclusion is shown by Ex12+ and skipping by Ex12 .
Figure 8. (A) Mouse and Human synthetic RNA sequences used in a aﬃnity puriﬁcation assay. Mouse speciﬁc nucleotides are boxed. (B) Pulldown
analysis performed for human and mouse CFTR exon 12 sequences spanning from nucleotide 18–39 were comparatively analyzed for splicing
factors. Harvested proteins were targeted for SR proteins (SRp 75, SRp 55, SRp 40, SF2/ASF) in western blot analysis. The membrane was later
probed with hnRNP A1 and U antibody. (C). Similar comparative analysis for splicing factors was performed for both the human and mouse CFTR
exon 12 sequences spanning nucleotides 64–82.
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CFTR exon 12 two regions, named CERES1 and
CERES2 (Figure 9), that functioned in a highly context-
dependent manner to regulate the splicing process of this
exon (44). In fact, the eﬀect of natural and artiﬁcial
mutations within these regions could not be predicted
easily using current bioinformatics approaches (44), high-
lighting recent recommendations that these programs
should be used with caution when they are used as a diag-
nostic tool (53,54). Indeed, successive experimental com-
parison between human and mouse CFTR exon 12
sequences demonstrated that about one quarter of all arti-
ﬁcial combinations of mouse–human same sense
substitutions resulted in exon skipping (40). Taken
together, these ﬁndings suggested that the whole coding
sequence of CFTR exon 12 is under strong selective
pressures not only for functional reasons at the protein
level, but also for the maintenance of proper exon recog-
nition by the splicing machinery.
Up to now, however, the detailed molecular bases of
CERES action were not known. We have performed an
analysis of the trans-acting factors that bind the CERES2
element localized in CFTR exon 12. Our analysis was
preliminarily focused at characterizing the binding
properties of the most common splicing regulators, and
in particular those belonging to either the SR or the
hnRNP class of trans-acting factors. The results of our
analysis have demonstrated that in normal conditions
human CERES2 can bind a substantial number of these
proteins, something that may be rather surprising since the
core CERES2 element represents a very short stretch of
RNA sequence (<10 nucleotides). Among SR proteins, we
have found SF2/ASF and SRp55 whilst regarding hnRNP
proteins speciﬁc binding could be detected for most
hnRNP A/B family members. Most importantly, the
relative binding capacity of some of the factors was
modiﬁed following the introduction of disease-associated
missense mutations or of samesense substitutions that
were already known to aﬀect CFTR exon 12 inclusion
levels. From a basic RNA binding protein point of view,
this ﬁnding highlights the great ﬂexibility provided by
RRM motifs that can recognize a few speciﬁc bases at
selected positions using their main chains and then use
side-chain interactions to stabilize binding (55). This
probably explains why the CERES2 sequence rather
than functioning as a binding site for a single protein
only can function as a kind of aggregation site for many
SR/hnRNP factors. Evidence of a functional interaction
was conﬁrmed only for SF2/ASF, SRp55 and hnRNP A1.
However, it should be noted that these experiments were
performed in a severely reduced context (mini-exon 12)
and that in a more natural setting many of these
proteins will be able to play a role, especially considering
the fact that the exonic ﬂanking regions also can bind
several SR/hnRNP factors (see below). At the moment,
of course, we have tested only few regulatory proteins
and hence cannot rule out the presence of additional yet
unknown factors that might also contribute to deﬁne/
hinder CFTR exon 12. Another possibility is that our
substitutions may aﬀect the RNA secondary structure of
CFTR exon 12. However, an evolutionary-based model of
CFTR exon 12 RNA secondary structure has already been
previously published by Meyer and Miklos (56). In their
work, they have also analyzed the potential impact of
some splicing mutations including substitutions in the
40T and 52C positions. The conclusion is that there are
only marginally signiﬁcant changes in the RNA structure
of the mutants with respect to the predicted wild-type
sequence. It is for this reason that we decided to concen-
trate on analyzing trans-acting factors rather than taking
Figure 9. Schematic comparison and conservation of the splicing regulatory elements (ESEs, ESSs, and CERES) in diﬀerent species based on our
functional analysis.
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stitutions.
Taken together, our results suggest that this crowding
together of many diﬀerent proteins (both positive and
negative in terms of their eﬀect on splicing) may explain
why single-point substitutions within the CERES2
element have such an unpredictable eﬀect on the exon
recognition levels. Up to now, on a slightly wider scale
the CERES sequence situation is similar to what has
already been found in several small exons, such as SMN
exon 7, where trans-acting factors (SF2/ASF and hnRNP
A1) binding to the same exonic region contribute to exon
inclusion/skipping (57,58). Other examples of very
complex systems include the human c-src exon N1
(59,60), CD44 exon v5 (61–63), HipK3 ‘T’ exon (64), and
chicken cTNT exon 5 (65) where numerous factors have
been shown to participate in splicing regulation in close
spatial proximity to each other. Indeed, for SMN exon 7 it
has been hypothesized the existence of an Extended
Inhibitory Context (Exinct) that is caused by overlapping
regulatory motifs not all of which have still been
characterized in depth (66).
On a more general note, the existence of these numerous
splicing factor binding sites co-existing together on the
same exon has very important implications with regards
to evolutionary constraints in codon composition. For
example, our results have shown very clearly that the
inhibitory eﬀect of some synonymous nucleotide
substitutions (A40T and C52T) naturally occurring in
the mouse sequence can be explained by the diﬀerent
splicing regulatory properties of the human and mouse
ﬂanking exonic sequences (summarized in Figure 9).
In particular, by comparing the ESE, ESS, and CERES
elements several considerations can be made with regards
to the sequence changes that have occurred in the mouse
to human transition during the course of evolution. In
fact, as shown in Figure 9 it can be hypothesized that
the creation of the human CERES2 element in CFTR
exon 12 has relieved the pressure to keep the two weak
ESE elements loosely localized in the mouse 18–39 and
64–82 ﬂanking regions. Only after the creation of
CERES2 element these two regions could thus undergo
nucleotide substitutions that either weakened these
elements (i.e. in the Ground squirrel and Guinea pig
64–82 region) or even changed them to functional
silencer sequences (in human 18–39 and 64–82 region).
The advantage of these coding region changes can be
only hypothesized at this stage, but it may involve
further steps beyond mRNA processing such as enzymatic
activity or protein stability. Irrespective of their signiﬁ-
cance, however, the important issue is that sequence
changes could only be introduced through the creation
of the CERES2 element (the importance of which is
highlighted by the observation that many of the mouse
to human substitutions analyzed in this study lead
directly to total exon skipping). It is also interesting to
note that a comparison of these sequence elements also
in other species (Figure 9) does not contradict the
conclusions we have drawn from mouse versus humans.
In fact, for example, both cows and rabbits that do not
contain the CERES2 element have absolutely conserved
ESE sequences. Of course, additional experiments will
need to be performed before we can draw ﬁrm conclusions
on this issue. Nonetheless, in our work, we show that an
integrated analysis of cis- and trans-acting factors binding
to exonic elements can provide a substantial wealth of
information on potential evolutionary mechanisms.
Looking at the splicing regulatory elements in Figure 9
it is also possible to draw some additional conclusions
with regards to our understanding of splicing regulation
in general. It is clear that, the CFTR exon 12 sequence is
literally covered by regulatory elements that we probably
still consider (rather mistakenly) as separate elements.
Proof of this is the observation that the activity of many
of these splicing regulatory elements (especially CERES)
cannot be exported in diﬀerent contexts (44). Indeed,
our results point towards a situation where in exons like
CFTR exon 12 we should virtually consider every
nucleotide as potentially capable of aﬀecting splicing
inclusion levels. The only question that might then
remain to us is the direction of this change (whether
increased inclusion/skipping) and its extent. It is very
probable that as our knowledge of splicing systems
increases this kind of situations will be more and more
common. From a practical point of view, this will have
several consequences. From a clinical point of view,
increased importance have to be given at analyzing
RNA transcripts directly from patient tissues or,
routinely, through minigene based systems that will
mimic this kind of global splicing regulatory networks
(67). Second, this increased awareness will be useful for
the development of novel bioinformatics methods aimed
at predicting splicing outcomes that, until now, have been
primarily focused at considering enhancer and silencer
elements as well distinct entities with rather limited
success (53,54). Finally, it should gradually shift our
view of splicing where exon inclusion levels should not
always be viewed as the straightforward algebraic sum
of enhancer/silencer elements but as rather as an
integrated unit, where silencing and enhancing functions
may functionally overlap to a degree that has often been
underestimated.
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